In a genomic analysis of breast cancers that were resistant to CDK4/6 inhibitors, loss-of-function mutations were found in the FAT1 gene, and the knockout of FAT1 conferred resistance to CDK4/6 inhibitors by the overexpression of the CDK6 protein via the suppression of the Hippo pathway34. This evidence concerns the gene CDK6 and breast cancer.